Anti-tumor effects of the oral administration of the streptococcal preparation OK-432 (PICIBANIL) - the inhibition of carcinogenesis and growth in rats with ENNG-induced gastrointestinal tumors.

Autor: Takeshita, Masaaki, Makita, Fujio, Takeyoshi, Izumi, Ishikawa, Hitoshi, Nakamura, Seiji, Owada, Susumu, Miyamoto, Yukio, Izuo, Masaru, Kurashige, Satonori
Zdroj: Japanese Journal of Surgery; May1990, Vol. 20 Issue 3, p316-326, 11p
Abstrakt: We examined whether the Streptococcal preparation OK-432, an immunopotentiating agent, increases immunocompetence of the gut-associated lymphoid system (GALS), inhibits gastrointestinal carcinogenesis, and has an anti-tumor effect.C-labelled OK-432 was orally and intraperitoneally administered to rats, and the distribution of the agent in various organs then serially evaluated. The concentration of OK-432 in Peyer's patches and mesenteric lymph nodes was higher after oral administration than after intraperitoneal administration, and showed a biphasic pattern peaking at 30 minutes and 5 hours following administration, in the Peyer's patches. With regard to immunocompetence, PHA- and PWM-stimulated blastogenesis of lymphocytes derived from the mesenteric lymph nodes and peripheral blood enhanced, and the helper/suppressor T-cell ratio was elevated after the oral administration of OK-432. Moreover, chemotactic activity of peritoneal macrophages was also increased. ENNG-induced gastrointestinal carcinogenesis was observed in 60 per cent of the rats orally administered OK-432 as compared with 88 per cent of the controls. The 13-month survival rate of the rats with gastrointestinal cancer was 50 per cent in those administered OK-432 as compared with 25 per cent in those administered OK-432 as compared with 25 per cent in the controls. When administered orally, the agent prevented reduction in immunocompetence in the course of carcinogenesis, suppressed carcinogenesis, and prolonged the survival of animals with cancer without any of the side effects associated with injection. The oral administration of OK-432 is thus considered to be an effective non-specific immunotherapy against gastrointestinal malignancies. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: